A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy

Ornstein, Moshe C ; Wood, Laura S ; Hobbs, Brian P ; Allman, Kimberly D ; Martin, Allison ; Bevan, Michael ; Gilligan, Timothy D ; Garcia, Jorge A ; Rini, Brian I

Journal for immunotherapy of cancer, 2019-05, Vol.7 (1), p.127-5, Article 127 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível